AI Engines For more Details: Perplexity Kagi Labs You
Alpha-Adrenergic Blockade: Phenoxybenzamine is a non-selective alpha-adrenergic antagonist, meaning it blocks the action of adrenaline and noradrenaline on both alpha-1 and alpha-2 adrenergic receptors. By blocking these receptors, it causes vasodilation (widening of blood vessels) and reduces the effects of sympathetic nervous system activation, leading to a decrease in blood pressure.
Treatment of Pheochromocytoma: Phenoxybenzamine is particularly effective in the management of pheochromocytoma, a rare tumor of the adrenal gland that produces excess catecholamines (epinephrine and norepinephrine). By blocking the alpha-adrenergic receptors, phenoxybenzamine helps control hypertension and reduces the risk of hypertensive crisis associated with pheochromocytoma.
Orthostatic Hypotension: One of the side effects of phenoxybenzamine is orthostatic hypotension, which is a sudden drop in blood pressure upon standing up from a lying or sitting position. This can lead to dizziness, lightheadedness, or even fainting. Patients should be advised to change positions slowly to minimize this risk.
Reflex Tachycardia: Phenoxybenzamine-induced vasodilation can trigger reflex tachycardia (rapid heart rate) as the body attempts to compensate for the decrease in blood pressure. This effect may be more pronounced in some individuals, particularly those with pre-existing cardiovascular conditions.
Nasal Congestion: Phenoxybenzamine can cause nasal congestion as a result of its alpha-blocking effects on blood vessels in the nasal mucosa. This side effect may be bothersome for some patients but is generally mild and transient.
Gastrointestinal Effects: Gastrointestinal side effects such as nausea, vomiting, and diarrhea may occur with phenoxybenzamine use. These effects are usually mild and may improve with continued use or dose adjustment.
Urinary Retention: Phenoxybenzamine may impair bladder function and lead to urinary retention, particularly in men with prostatic hypertrophy. Patients should be monitored for urinary symptoms and advised to seek medical attention if they experience difficulty urinating.
Ocular Effects: Phenoxybenzamine can cause miosis (pupil constriction) and blurred vision due to its effects on alpha-adrenergic receptors in the eye. Patients should use caution when driving or operating machinery, especially in low-light conditions.
Edema: Peripheral edema (swelling of the extremities) may occur as a result of fluid redistribution caused by phenoxybenzamine-induced vasodilation. Patients with heart failure or renal impairment may be at increased risk of developing edema.
Hypotension During Surgery: Phenoxybenzamine is sometimes used preoperatively to control blood pressure during surgical removal of pheochromocytoma. Careful monitoring of blood pressure and hemodynamic parameters is essential during surgery to prevent hypotension and maintain adequate perfusion to vital organs.
Interactions: Phenoxybenzamine may interact with other medications, particularly other antihypertensive drugs, leading to additive effects on blood pressure. Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal supplements.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 1 | 1 | |
Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.1 | 1 |
Allergic Rhinitis (Hay Fever) | 1.4 | 1.4 | |
Allergies | 1.6 | 0.3 | 4.33 |
Allergy to milk products | 0.5 | 0.3 | 0.67 |
Alopecia (Hair Loss) | 0.4 | 0.4 | |
Alzheimer's disease | 1.4 | 3.1 | -1.21 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.3 | 2 |
Ankylosing spondylitis | 1.2 | 1.2 | 0 |
Anorexia Nervosa | 0.1 | 1.1 | -10 |
Antiphospholipid syndrome (APS) | 1 | 1 | |
Asthma | 0.4 | -0.4 | |
Atherosclerosis | 0.7 | -0.7 | |
Atrial fibrillation | 1.1 | 0.8 | 0.38 |
Autism | 3 | 2.7 | 0.11 |
Barrett esophagus cancer | 0.1 | 0.1 | |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Biofilm | 1.2 | 1.2 | |
Bipolar Disorder | 0.5 | 0.3 | 0.67 |
Brain Trauma | 0.4 | -0.4 | |
Carcinoma | 0.9 | 0.7 | 0.29 |
Celiac Disease | 0.6 | 0.9 | -0.5 |
Cerebral Palsy | 0.1 | 0.8 | -7 |
Chronic Fatigue Syndrome | 2.5 | 1.7 | 0.47 |
Chronic Kidney Disease | 2.4 | 0.7 | 2.43 |
Chronic Lyme | 0.4 | -0.4 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.3 | -2 |
Chronic Urticaria (Hives) | 0.5 | 0.9 | -0.8 |
Coagulation / Micro clot triggering bacteria | 0.6 | 0.6 | 0 |
Colorectal Cancer | 1.6 | 0.2 | 7 |
Constipation | 0.4 | 0.6 | -0.5 |
Coronary artery disease | 1.1 | 0.5 | 1.2 |
COVID-19 | 2.9 | 3.7 | -0.28 |
Crohn's Disease | 3.4 | 2.1 | 0.62 |
cystic fibrosis | 0.5 | 0.4 | 0.25 |
deep vein thrombosis | 0.5 | 0.2 | 1.5 |
Depression | 2.5 | 2 | 0.25 |
Eczema | 1.1 | 0.6 | 0.83 |
Endometriosis | 1.2 | 0.1 | 11 |
Eosinophilic Esophagitis | 0.1 | -0.1 | |
Epilepsy | 1.3 | 1 | 0.3 |
Fibromyalgia | 1 | 1 | 0 |
Functional constipation / chronic idiopathic constipation | 1.9 | 2.3 | -0.21 |
gallstone disease (gsd) | 0.7 | 0.2 | 2.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.8 | -0.14 |
Generalized anxiety disorder | 1.7 | 0.2 | 7.5 |
Graves' disease | 0.3 | 0.6 | -1 |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 1.8 | 0.2 | 8 |
Hidradenitis Suppurativa | 0.1 | -0.1 | |
High Histamine/low DAO | 0.5 | 0.5 | |
hyperglycemia | 0.2 | 0.7 | -2.5 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 0.5 | 1.6 | -2.2 |
Hypothyroidism | 0.4 | -0.4 | |
Hypoxia | 0.3 | 0.3 | |
IgA nephropathy (IgAN) | 2 | -2 | |
Inflammatory Bowel Disease | 2.1 | 2.9 | -0.38 |
Insomnia | 0.6 | 0.5 | 0.2 |
Intelligence | 0.5 | 0.3 | 0.67 |
Intracranial aneurysms | 0.7 | 0.7 | |
Irritable Bowel Syndrome | 1.2 | 1.2 | 0 |
Liver Cirrhosis | 1.2 | 0.5 | 1.4 |
Long COVID | 2.3 | 2.3 | 0 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0.2 | 0.4 | -1 |
Mast Cell Issues / mastitis | 0.2 | 0.2 | |
ME/CFS with IBS | 1 | -1 | |
ME/CFS without IBS | 1 | 0.2 | 4 |
Metabolic Syndrome | 2.9 | 2 | 0.45 |
Mood Disorders | 2.7 | 2 | 0.35 |
multiple chemical sensitivity [MCS] | 0.1 | 0.4 | -3 |
Multiple Sclerosis | 0.5 | 2 | -3 |
Multiple system atrophy (MSA) | 0.4 | -0.4 | |
neuropathic pain | 0.3 | -0.3 | |
Neuropathy (all types) | 0.4 | 0.2 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 1.8 | -1 |
NonCeliac Gluten Sensitivity | 0.4 | 0.2 | 1 |
Obesity | 3 | 0.7 | 3.29 |
obsessive-compulsive disorder | 2.7 | 3 | -0.11 |
Osteoarthritis | 1.3 | 1.3 | |
Osteoporosis | 0.4 | 0.6 | -0.5 |
Parkinson's Disease | 2.3 | 2.6 | -0.13 |
Polycystic ovary syndrome | 0.9 | 0.2 | 3.5 |
Premenstrual dysphoric disorder | 0.4 | 0.1 | 3 |
primary biliary cholangitis | 0.5 | -0.5 | |
Psoriasis | 1.3 | 0.9 | 0.44 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 1.1 | 1.18 |
Rosacea | 1 | 0.2 | 4 |
Schizophrenia | 1 | 0.6 | 0.67 |
scoliosis | 0.1 | -0.1 | |
Sjögren syndrome | 1.2 | 1.4 | -0.17 |
Sleep Apnea | 0.4 | 0.8 | -1 |
Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Stress / posttraumatic stress disorder | 0.9 | 0.4 | 1.25 |
Systemic Lupus Erythematosus | 2.4 | 0.7 | 2.43 |
Tic Disorder | 0.3 | -0.3 | |
Tourette syndrome | 0.2 | -0.2 | |
Type 1 Diabetes | 1.4 | 0.3 | 3.67 |
Type 2 Diabetes | 2.9 | 2.5 | 0.16 |
Ulcerative colitis | 1 | 1.4 | -0.4 |
Unhealthy Ageing | 2.7 | 0.6 | 3.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. i > p >
Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models a > and may not be accurate and include some hallucinations em >.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [44.222.131 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.131 ]